Patient JourneyFAQsClinical StudiesPost-Procedure InstructionsTestimonialsContact

Mesenchymal Stem Cell Therapy in Istanbul, Turkey

The most clinically studied class of regenerative cell therapy. Learn how mesenchymal stem cells work, where they come from, what conditions they support, and how MSC programs are delivered at our Istanbul clinic.

What Is Mesenchymal Stem Cell Therapy?

Mesenchymal stem cell therapy is a regenerative medicine approach that uses multipotent stromal cells — mesenchymal stem cells (MSCs) — to support tissue repair, modulate the immune system, and reduce inflammation. MSCs are administered via intravenous, intrathecal, intra-articular, or localized injection, depending on the clinical target.

The therapeutic effect of MSCs is driven primarily by paracrine signaling — the bioactive molecules they secrete — rather than long-term engraftment. MSCs secrete growth factors, anti-inflammatory cytokines, and exosomes that influence the surrounding cellular environment and recruit the body's own repair machinery.

How Mesenchymal Stem Cells Work

Paracrine signaling

MSCs secrete growth factors (VEGF, HGF, IGF-1, BDNF), anti-inflammatory cytokines (IL-10, TGF-β), and chemokines that orchestrate local tissue repair.

Immunomodulation

MSCs engage T cells, B cells, NK cells, and macrophages — shifting the immune environment from inflammatory toward regulatory and repair-oriented.

Extracellular vesicle release

MSCs package bioactive cargo — proteins, mRNA, microRNAs — inside exosomes that travel to distant tissues and modulate gene expression.

Tissue homing

Infused MSCs migrate preferentially toward sites of injury, inflammation, or hypoxia where their paracrine output has the greatest local impact.

Neurotrophic support

For neurological indications MSCs and their exosomes deliver BDNF, NGF, and GDNF — supporting neuronal survival and synaptic function.

Multipotent differentiation

MSCs can differentiate into bone, cartilage, muscle, and fat lineages — although clinical benefit is dominated by paracrine and immunomodulatory effects, not direct differentiation.

Sources of Mesenchymal Stem Cells

MSCs can be harvested from several adult tissues. Source dramatically affects potency, scalability, and clinical performance.

SourcePotencyNotes
Umbilical Cord (Wharton's Jelly)HighestNeonatal — longest telomeres, strongest paracrine output, immune-privileged. Standard at TurkeyStemcell.
Bone MarrowModerateAdult MSCs — proven safety but lower yield, more donor variability, requires invasive harvest.
Adipose TissueModerateAdult MSCs harvested via liposuction. Higher yield than bone marrow but more donor variability.
Placenta / AmnioticHighNeonatal source with strong potency but more limited clinical and supply-chain availability.
Dental PulpVariableEmerging clinical source — primarily research stage.

TurkeyStemcell uses Wharton's jelly–derived MSCs in all clinical protocols. Learn more on our Wharton's jelly stem cells page.

Conditions Evaluated for MSC Therapy

Multiple SclerosisParkinson's DiseaseALSAutism SupportCerebral PalsyKnee OsteoarthritisRheumatoid ArthritisLupusCrohn's DiseaseType 2 DiabetesCOPDAnti-Aging Wellness

Frequently Asked Questions

Mesenchymal stem cell therapy is a regenerative medicine approach that uses multipotent stromal cells — mesenchymal stem cells — to support tissue repair, modulate inflammation, and regulate immune function. MSCs are administered via intravenous, intrathecal, intra-articular, or localized injection depending on the clinical target. The therapeutic effect is driven primarily by paracrine signaling — the bioactive molecules MSCs secrete — rather than long-term engraftment.

Mesenchymal stem cells (MSCs) are adult multipotent stromal cells capable of differentiating into mesodermal lineages including bone (osteoblasts), cartilage (chondrocytes), muscle (myocytes), and fat (adipocytes). They can be sourced from bone marrow, adipose tissue, umbilical cord (Wharton's jelly), placenta, and dental pulp. MSCs are identified by surface marker expression (CD73+, CD90+, CD105+, CD34−, CD45−) per the International Society for Cell & Gene Therapy (ISCT) criteria.

MSCs exert therapeutic effects through three main mechanisms. (1) Paracrine signaling — secreting growth factors (VEGF, HGF, IGF-1, BDNF), anti-inflammatory cytokines (IL-10, TGF-β), and immunomodulatory molecules (IDO, PGE2). (2) Immunomodulation — directly engaging T cells, B cells, NK cells, and macrophages to shift the immune environment toward repair. (3) Extracellular vesicle release — packaging bioactive cargo (proteins, mRNA, microRNA) inside exosomes for delivery to distant tissues.

Umbilical cord–derived MSCs from Wharton's jelly (WJ-MSCs) are generally considered the most potent clinical source. Compared to bone-marrow or adipose-derived MSCs they offer: stronger proliferative capacity, longer telomeres, superior anti-inflammatory output, and immune-privileged status (allowing allogeneic use without HLA matching). They are also ethically sourced from tissue that would otherwise be discarded.

MSC therapy is studied across a broad range of indications including neurological conditions (MS, Parkinson's, ALS, stroke, TBI, spinal cord injury, autism, cerebral palsy), orthopedic conditions (osteoarthritis, knee, hip, shoulder), autoimmune disease (rheumatoid arthritis, lupus, Crohn's), pulmonary disease (COPD), endocrine support (Type 1 and Type 2 diabetes), and anti-aging wellness. MSC therapy is supportive, not curative — outcomes vary by indication, disease stage, and individual response.

Administration routes are chosen based on the clinical target. Intravenous (IV) infusion is standard for systemic inflammatory or autoimmune conditions. Intrathecal (lumbar-puncture) delivery targets the central nervous system for MS, ALS, Parkinson's, autism, and other neurological indications. Intra-articular injection is used for osteoarthritis and joint cartilage support. Localized injection delivers cells directly to target tissue. Many advanced protocols combine routes within a single program.

Allogeneic Wharton's jelly–derived MSC therapy has an excellent safety profile across hundreds of published clinical studies. Because MSCs are immune-privileged, allogeneic administration does not require HLA matching or immunosuppression. Common transient effects include mild fatigue, low-grade fever, or short-lived headache lasting 24–48 hours. Serious adverse events are extremely rare when cells are sourced and processed in GMP-certified facilities.

FDA approval status varies by jurisdiction and indication. In the United States, no allogeneic MSC therapy product is currently FDA-approved as a general regenerative therapy — most clinical MSC programs are delivered under research protocols, expanded access, or international clinical settings. Outside the US, MSC therapy is provided as a clinical regenerative protocol in countries including Turkey under Ministry of Health oversight comparable to EU regulatory standards.

At TurkeyStemcell, MSC therapy programs range from approximately $5,900 for a single-session wellness IV protocol to $22,000 for advanced multi-day neurological programs. This is 50–70% less than equivalent treatment at clinics in the United States or Western Europe. See our detailed stem cell therapy cost page for a full per-condition breakdown.

Response timelines vary by condition and individual. Some patients report noticeable improvements within 2–4 weeks of infusion, while full regenerative and immunomodulatory effects may continue developing over 3–6 months as MSC-derived signaling molecules support tissue repair, inflammation resolution, and cellular communication. Structured remote follow-up at 1, 3, 6, and 12 months tracks progress objectively.

TurkeyStemcell operates a fully equipped regenerative medicine clinic in Istanbul, Turkey, serving international patients from 40+ countries. Our facility includes GMP-certified MSC processing, specialist consultation, multilingual care coordination, and structured remote follow-up. Book a free consultation to receive a personalized protocol recommendation.

Explore a Personalized MSC Protocol

Free consultation with our regenerative medicine specialists. Personalized protocol recommendation and written quote within 24 hours.

Request Free ConsultationWhatsApp Us

Or call directly: +90 534 856 92 92